A Review on Epidemiology of Liver Diseases and Current Treatment Modalities for Liver Disorders

Abstract

Liver diseases pose a significant global health challenges, Liver diseases constitute a major and escalating global health concern, responsible for approximately two million deaths each year—accounting for nearly 4% of all global mortality, or one in every 25 deaths worldwide. The etiology of chronic liver disease is multifactorial and varies geographically, with the leading global causes including chronic viral hepatitis (HBV and HCV), alcohol-related liver disease (ALD), and non-alcoholic fatty liver disease (NAFLD), recently redefined as metabolic dysfunction-associated fatty liver disease (MAFLD).Live damage happened in various stages which included oxidative stress, mitochondrial dysfunction, inflammation and cytokine cascade, apoptosis and necrosis: the intrinsic (mitochondrial) pathway and the extrinsic pathway. Therapeutic regimens typically involve a combination of pharmacological agents that address viral replication, immune deregulation, inflammatory pathways, cholestasis, and disease-related complications. Liver transplantation (LT) represents the definitive treatment for patients with end-stage liver disease (ESLD), acute liver failure, or early-stage hepatocellular carcinoma (HCC) that is not amenable to surgical resection. Future work should focus on isolation and characterization of active constituents, detailed pharmacokinetic and toxicological profiling, and clinical trials to validate its safety and efficacy in humans.

Keywords

Introduction

Figure 1: Anatomy of Liver.

Figure 2: Micronutrient storage and metal metabolism.

Figure 3: Liver disease burden in India – National Statistic (2020-2025)

Figure 4: Pathophysiology of liver injury.

Common Types of Liver Disorders:

1. Alcoholic Liver Disease (ALD):

It is a major cause of liver-related morbidity and mortality worldwide, resulting from chronic and excessive alcohol consumption. ALD progresses along a well-recognized clinical continuum—beginning with simple steatosis, advancing to alcoholic steatohepatitis (ASH), and further evolving into fibrosis, cirrhosis, and ultimately alcohol-related hepatocellular carcinoma (HCC). In India, where alcohol use was traditionally limited by cultural and religious factors, recent shifts in societal norms and increased alcohol consumption particularly among males aged 25–55 years have significantly contributed to the growing prevalence of ALD ^[9,10,11,12].

The pathogenesis of ALD is multifactorial and complex. It involves several interrelated mechanisms:

• Oxidative stress arising from chronic ethanol metabolism.
• Accumulation of acetaldehyde, a toxic intermediate metabolite of alcohol.
• Cytokine-mediated inflammation, particularly involving tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6).
• Lipid peroxidation and excessive production of reactive oxygen species (ROS)
• Endotoxemia, caused by increased intestinal permeability and translocation of bacterial lipopolysaccharides.

2. Non-Alcoholic Fatty Liver Disease (NAFLD):

It has become the most common cause of chronic liver disease worldwide, currently affecting approximately 25–30% of adults. NAFLD encompasses a spectrum of hepatic disorders, beginning with non-alcoholic fatty liver (NAFL) characterized by simple steatosis without significant inflammation—and progressing to non-alcoholic steatohepatitis (NASH), which involves inflammation, hepatocyte injury, and ballooning degeneration. If untreated, NASH can lead to fibrosis, cirrhosis, and ultimately hepatocellular carcinoma (HCC) ^[13,14,15].

The pathophysiology of NAFLD is multifactorial and includes:

• Lipotoxicity, resulting from the accumulation of free fatty acids.
• Mitochondrial dysfunction, leading to impaired β-oxidation and energy imbalance.
• Endoplasmic reticulum (ER) stress, contributing to cellular injury.
• Oxidative stress and excess reactive oxygen species (ROS) production.
• Chronic inflammation, often exacerbated by cytokine release and gut microbiota dysbiosis.

3. Drug-Induced Liver Injury (DILI):

It is a leading cause of acute liver failure and presents a considerable challenge in both clinical settings and pharmaceutical development. It is broadly classified into two major types: intrinsic DILI, which is dose-dependent, predictable, and typically associated with direct hepatotoxicity—as exemplified by acetaminophen (paracetamol) overdose; and idiosyncratic DILI, which is dose-independent, unpredictable, and thought to be influenced by genetic predispositions or immunologic hypersensitivity. In the Indian context, DILI is most commonly associated with anti-tubercular therapy (ATT), particularly involving drugs such as isoniazid, rifampicin, and pyrazinamide. Other frequently implicated agents include non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics, chemotherapeutic agents, and herbal or traditional remedies, many of which are used without appropriate medical oversight, thereby increasing the risk of hepatotoxicity ^[16].

4. Viral Hepatitis (A–E):

It caused by hepatotropic viruses A through E, continues to be a significant global public health challenge, particularly affecting regions in Asia and Africa. These infections vary in transmission routes, clinical outcomes, and long-term complications, but collectively contribute to substantial liver-related morbidity and mortality ^[17,18].

Hepatitis A virus (HAV) and Hepatitis E virus (HEV) are both transmitted via the fecal-oral route, most often through ingestion of contaminated food or water ^[17,18].

Hepatitis B virus (HBV) is a DNA virus that causes both acute and chronic hepatitis. Among individuals with chronic HBV infection, approximately 15–40% progress to cirrhosis or hepatocellular carcinoma (HCC) ^[17,19,20].

Hepatitis C virus (HCV) is an RNA virus transmitted primarily via parenteral routes, including unsafe injections, blood transfusions, and needle sharing. Chronic HCV infection frequently leads to progressive liver fibrosis, cirrhosis, and HCC, making it a leading indication for liver transplantation globally ^[19,21,22].

Hepatitis D virus (HDV) is a defective RNA virus that requires co-infection with HBV for replication. Co-infection or superinfection with HDV leads to more aggressive liver disease, rapidly accelerating the progression to cirrhosis and HCC compared to HBV monoinfection^[18,21,22].

Comprehensive control of viral hepatitis relies on early diagnosis, effective antiviral treatment, mass vaccination programs (particularly against HAV and HBV), and public health education to reduce risk exposures. Preventive measures such as improved sanitation, safe injection practices, and blood safety protocols are fundamental. As such, viral hepatitis remains not only a medical but also a social and infrastructural challenge that requires integrated, long-term public health strategies ^[20].

5. Autoimmune Liver Diseases:

This is chronic inflammatory conditions that arise due to a loss of immune tolerance, resulting in an inappropriate immune response directed against hepatocytes or biliary epithelial cells. These diseases are characterized by immune-mediated hepatic injury and can lead to progressive liver damage if not adequately managed. The three principal forms include Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), and Primary Sclerosing Cholangitis (PSC) ^[23].

6. Genetic and Congenital Liver Disorders:

Inherited liver diseases, though relatively uncommon, represent significant causes of hepatic dysfunction, often presenting in childhood or early adulthood. Among the most clinically relevant are Wilson’s Disease (WD) and Alpha-1 Antitrypsin Deficiency (A1ATD), both of which require early recognition to prevent irreversible liver damage ^[24,25,26].

7. Liver Cirrhosis and Hepatocellular Carcinoma (HCC):

Cirrhosis represents the final stage of chronic liver injury and is characterized by widespread hepatic fibrosis, formation of regenerative nodules, and significant vascular remodeling. It results from prolonged hepatocellular damage caused by various underlying conditions, most notably alcoholic liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), chronic viral hepatitis (HBV and HCV), and autoimmune liver diseases. These chronic insults disrupt normal liver architecture and compromise its physiological functions, leading to irreversible liver damage. The clinical manifestations of cirrhosis vary depending on the stage and severity but commonly include complications such as ascites, resulting from portal hypertension and hypoalbuminemia; hepatic encephalopathy, due to the accumulation of neurotoxins like ammonia; variceal bleeding, stemming from esophageal or gastric varices; and coagulopathy, owing to impaired synthesis of clotting factors. These complications signify hepatic decompensation and are associated with increased morbidity and mortality ^[8,27].

Recent Evidence Has Revealed Other Regulated Cell Death Pathways In Liver Pathology:

In addition to apoptosis and necrosis, several emerging forms of regulated cell death have been identified as critical contributors to liver pathology, each with distinct molecular mediators and implications for disease progression and therapy.

Necroptosis is a form of programmed necrosis that occurs when apoptotic pathways are inhibited. It is mediated by key signaling molecules including receptor-interacting protein kinases 1 and 3 (RIPK1 and RIPK3) and the mixed lineage kinase domain-like protein (MLKL). Upon activation, MLKL translocates to the plasma membrane, causing its rupture and the release of pro-inflammatory intracellular contents. Necroptosis has been implicated in conditions such as drug-induced liver injury (DILI) and non-alcoholic fatty liver disease (NAFLD), where it contributes to hepatocellular damage and inflammation ^[28].

Pyroptosis is a highly inflammatory form of cell death mediated by caspase-1 activation and the pore-forming protein gasdermin D (GSDMD). This process is closely linked to NLRP3 inflammasome activation, which occurs in response to cellular stress and damage signals. Pyroptosis plays a critical role in innate immune responses and has been associated with the pathogenesis of NASH, alcoholic hepatitis, and autoimmune hepatitis ^[28,29].

Ferroptosis is a distinct iron-dependent cell death pathway characterized by accumulation of lipid peroxides, driven by impaired glutathione peroxidase 4 (GPX4) activity. Unlike apoptosis or necrosis, ferroptosis is triggered by iron overload and oxidative lipid damage, and is increasingly recognized in the context of hepatocarcinogenesis, ischemia-reperfusion injury, and liver fibrosis. These novel mechanisms of cell death not only deepen our understanding of liver disease pathophysiology but also unveil promising therapeutic targets. Modulating necroptosis, pyroptosis, or ferroptosis may offer new strategies for hepatoprotection and disease modification, especially in settings where conventional therapies are limited ^[28].

Biomarkers of Liver Damage:

Biochemical markers play a vital role in the diagnosis and management of liver diseases. They serve as key indicators for detecting hepatocellular injury, determining the underlying etiology, tracking disease progression, and evaluating the therapeutic response. These markers broadly reflect three major aspects of liver function: hepatocyte integrity, biliary function, and synthetic capacity. Assessing this biochemical profile enables clinicians to identify the extent and nature of hepatic damage, differentiate between various liver disorders, and guide clinical decision-making for both acute and chronic liver conditions ^[11].

1. Alanine Aminotransferase (ALT): It is a cytoplasmic enzyme primarily localized within hepatocytes and is regarded as the most liver-specific aminotransferase. It serves as a highly sensitive biomarker for detecting hepatocellular injury. Elevated ALT levels are commonly observed in conditions such as acute viral hepatitis, drug-induced liver injury (DILI), non-alcoholic fatty liver disease (NAFLD), and autoimmune hepatitis. Importantly, ALT levels often rise before the onset of clinical symptoms, positioning it as a reliable early indicator of liver damage and an essential component of liver function testing ^{[22, 30,32]}  .

2. Aspartate Aminotransferase (AST):  It is an enzyme found in both the cytosol and mitochondria of various tissues, including the liver, skeletal muscle, cardiac muscle, and kidneys. Although it is less specific to the liver than ALT, AST remains a valuable marker of hepatic injury, particularly in specific clinical contexts. In alcoholic liver disease (ALD), an AST/ALT ratio greater than 2 is considered diagnostically significant, suggesting mitochondrial damage, which is a hallmark of alcohol-induced hepatotoxicity. Additionally, elevated AST levels are often observed in advanced fibrosis and cirrhosis, reflecting progressive liver injury and structural remodeling ^[22,30,31].

3. Alkaline Phosphatase (ALP): It is a membrane-bound enzyme predominantly expressed in the epithelial cells of the bile ducts. It serves as a key marker of cholestasis and is typically elevated in cholestatic liver disorders such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and biliary obstruction due to stones or tumors. However, because ALP is also present in other tissues like bone and placenta, its elevation is not liver-specific. Therefore, concurrent measurement of gamma-glutamyl transferase (GGT) is essential to confirm the hepatic origin of elevated ALP levels, improving diagnostic specificity for liver-related pathology ^[22,31,32].

4. Gamma-Glutamyl Transferase (GGT): It is a highly sensitive marker for biliary epithelial injury and is frequently elevated in parallel with alkaline phosphatase (ALP) in cholestatic liver conditions. Its measurement is particularly useful in confirming the hepatic origin of raised ALP levels. Beyond cholestasis, GGT is commonly elevated in cases of chronic alcohol consumption, making it a supportive marker in the diagnosis of alcoholic liver disease. Additionally, GGT is used to monitor hepatic enzyme induction by certain drugs, such as anticonvulsants and barbiturates, due to its responsiveness to microsomal enzyme induction ^[31,33].

5. Total and Direct Bilirubin (TB and DB): Bilirubin is a metabolic byproduct formed during the catabolism of heme, primarily from the breakdown of hemoglobin in senescent red blood cells. It exists in two major forms: unconjugated (indirect) and conjugated (direct). Unconjugated bilirubin levels are elevated in conditions such as hemolysis and Gilbert syndrome, where hepatic uptake or conjugation is impaired. In contrast, conjugated bilirubin rises when there is hepatocellular dysfunction or cholestasis, due to impaired excretion into the bile canaliculi. Clinically significant elevations in direct bilirubin are commonly observed in viral hepatitis, alcoholic liver disease (ALD), non-alcoholic steatohepatitis (NASH), and obstructive jaundice, reflecting disrupted bile flow or hepatocellular excretory failure ^[31].

6. Serum Albumin: Albumin, synthesized exclusively by hepatocytes, serves as a key indicator of the liver’s synthetic function. It plays a critical role in maintaining plasma oncotic pressure and acts as a carrier protein for various endogenous and exogenous substances. Low serum albumin levels are indicative of chronic liver dysfunction, and may also reflect malnutrition or protein-losing conditions such as nephrotic syndrome or enteropathy. In clinical practice, serum albumin is an important parameter included in the Child-Pugh score, aiding in the assessment of liver disease severity and prognosis in patients with cirrhosis ^[34,35].

7. Prothrombin Time (PT) and International Normalized Ratio (INR): Prothrombin time (PT) and its standardized form, the international normalized ratio (INR), assess the liver’s ability to synthesize coagulation factors, particularly factors II, V, VII, IX, and X, which are all produced by hepatocytes. A prolonged PT/INR is a hallmark of hepatic synthetic failure and serves as a poor prognostic indicator, especially in conditions such as acute liver failure and advanced cirrhosis. PT/INR is also a critical component of the Model for End-Stage Liver Disease (MELD) score, which is widely used to evaluate disease severity and prioritize patients for liver transplantation ^[8,30].

8. Lactate Dehydrogenase (LDH): It is a non-specific marker of cellular injury and necrosis, widely distributed across various tissues. In the context of liver disease, elevated LDH levels are particularly associated with ischemic hepatitis and massive hepatic necrosis, where widespread hepatocyte death leads to significant enzyme release into the bloodstream. Although LDH lacks organ specificity, its marked elevation especially in combination with other liver enzymes can provide supportive evidence of acute hepatocellular damage in severe hepatic insults ^[36].

9. Emerging Biomarkers: Recent advances in molecular diagnostics have led to the identification of novel biomarkers that enhance the early detection, staging, and monitoring of liver diseases, particularly non-alcoholic steatohepatitis (NASH) and fibrosis progression. Among these, keratin-18 fragments serve as markers of hepatocyte apoptosis, providing insight into ongoing cell death in NASH. Circulating microRNAs, such as miR-122 and miR-34a, are liver-specific and have shown promise as sensitive indicators of hepatocellular injury. Markers of fibrogenesis, including hyaluronic acid, tissue inhibitor of metalloproteinase-1 (TIMP-1), and procollagen type III N-terminal peptide (PIIINP), reflect extracellular matrix remodeling and are being studied for their utility in fibrosis staging. Non-invasive scoring systems like the FIB-4 index and the AST to Platelet Ratio Index (APRI) integrate routine clinical parameters to estimate fibrosis severity, offering alternatives to liver biopsy. These biomarkers are currently under clinical evaluation for their effectiveness in early NASH diagnosis, tracking fibrosis progression, and monitoring therapeutic response in clinical trials, with the goal of improving patient stratification and outcome prediction in chronic liver disease ^[11].

CURRENT TREATMENT MODALITIES FOR LIVER DISORDERS:

Over the past two decades, the management of liver diseases has advanced substantially, owing to progress in virology, immunology, pharmacotherapeutics, and transplant medicine. Despite these developments, current treatment strategies remain largely etiology-specific and often have limited capacity to reverse advanced liver injury or restore full hepatic function. Therapeutic regimens typically involve a combination of pharmacological agents that address viral replication, immune dysregulation, inflammatory pathways, cholestasis, and disease-related complications.

1. Antiviral Therapies:

Antivirals are the cornerstone of treatment for chronic hepatitis B (HBV) and hepatitis C (HCV). HBV management relies on potent nucleos(t)ide analogues such as entecavir, tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF). These drugs inhibit HBV DNA polymerase, effectively suppress viral replication, reduce hepatic inflammation, and lower the risk of cirrhosis and hepatocellular carcinoma (HCC). However, due to the persistence of covalently closed circular DNA (cccDNA), complete viral eradication is rare, necessitating lifelong therapy for most patients. Resistance remains a concern with older agents such as lamivudine. For HCV, direct-acting antivirals (DAAs) have transformed the therapeutic landscape. Agents like sofosbuvir, ledipasvir, velpatasvir, and glecaprevir/ pibrentasvir target HCV proteins (NS3/4A protease, NS5A, NS5B polymerase), offering short-duration oral regimens (8–12 weeks) with cure rates exceeding 95% across genotypes. DAAs are generally well tolerated and effective in patients co-infected with HIV. Nevertheless, high treatment costs remain a barrier in low- and middle-income countries, including India, although generic options have improved accessibility ^[17,22].

2. Corticosteroids and Immunosuppressants:    

In autoimmune hepatitis (AIH) and severe alcoholic hepatitis (AH), corticosteroids remain first-line therapy. Prednisolone or methylprednisolone is used to induce remission in AIH, often combined with azathioprine for maintenance and steroid tapering. In cases of azathioprine intolerance or hepatotoxicity, alternatives include mycophenolate mofetil, tacrolimus, or cyclosporine. Regular monitoring of liver enzymes, serum IgG, and autoantibody titers is essential for guiding therapy and detecting relapse. In severe AH, corticosteroids are reserved for patients with a Maddrey Discriminant Function ≥32 or MELD score >20, provided contraindications such as active infection or gastrointestinal bleeding are absent. While pentoxifylline has been used as a TNF-α inhibitor, it is no longer favored due to limited efficacy. Emerging therapies such as interleukin-22 analogs, granulocyte colony-stimulating factor (G-CSF), and fecal microbiota transplantation (FMT) are under investigation for steroid non-responders ^[28].

3. Immunomodulation in Cholestatic Diseases:                                          

For primary biliary cholangitis (PBC), ursodeoxycholic acid (UDCA) remains the standard of care, improving biochemical parameters, delaying disease progression, and enhancing transplant-free survival. In UDCA non-responders, obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, is approved as a second-line therapy. In primary sclerosing cholangitis (PSC), effective pharmacologic options are limited. While low-dose UDCA may be used, high-dose regimens have shown adverse effects. Management focuses on symptom control, endoscopic therapy of biliary strictures, and cancer surveillance, particularly for cholangiocarcinoma ^[37].

4. Antioxidants and Emerging Agents:

N-acetylcysteine (NAC) is the treatment of choice for acetaminophen toxicity and is increasingly being evaluated for non-acetaminophen acute liver failure, especially when administered early. NAC acts by replenishing glutathione, neutralizing ROS, and improving hepatic microcirculation. For NAFLD and non-alcoholic steatohepatitis (NASH), investigational agents such as pioglitazone, vitamin E, GLP-1 receptor agonists (e.g., liraglutide), and SGLT2 inhibitors (e.g., empagliflozin) are showing promise. These agents target insulin resistance, oxidative stress, and hepatic lipid accumulation, though widespread regulatory approval is still pending ^[8].

5. Supportive and Symptom-Directed Therapies:

Supportive care remains fundamental, particularly in advanced cirrhosis. For hepatic encephalopathy, lactulose and rifaximin reduce ammonia production by altering gut flora. Ascites is managed with diuretics (spironolactone and furosemide), paracentesis, and albumin infusion to maintain circulatory stability. Non-selective beta-blockers (NSBBs) such as propranolol help reduce portal hypertension and prevent variceal bleeding. Other key interventions include antibiotic prophylaxis to prevent spontaneous bacterial peritonitis, nutritional support to address malnutrition and sarcopenia, and monitoring for complications such as HCC, renal dysfunction, and infections.

Together, these therapies form a comprehensive approach to managing liver disease. However, the persistent limitations in reversing fibrosis and restoring full hepatic function highlight the ongoing need for new therapeutic targets, particularly in antifibrotic, anti-inflammatory, and regenerative pathways.

Limitations And Side Effects:

While conventional therapies have undoubtedly improved the clinical management and prognosis of various liver diseases, they remain predominantly palliative, often aimed at symptom control or pathway-specific interventions rather than achieving complete reversal of hepatic injury or fibrosis. Many current treatments are associated with significant adverse effects, variable efficacy across patient subgroups, and limitations in targeting the underlying pathophysiology of chronic liver conditions. One of the most significant challenges in hepatology is the irreversibility of advanced fibrosis and cirrhosis. Even after successful viral suppression, the structural and functional restoration of the liver remains inconsistent. For example, direct-acting antivirals (DAAs) effectively eradicate HCV, but do not fully reverse established cirrhosis, and the risk of hepatocellular carcinoma (HCC) remains elevated for years post-treatment. In chronic hepatitis B, nucleos(t)ide analogues suppress viral replication but fail to eliminate covalently closed circular DNA (cccDNA), resulting in relapse upon therapy discontinuation. Although newer antivirals have reduced resistance rates, the issue persists, particularly in resource-limited settings with suboptimal adherence.

Corticosteroids, which are first-line agents in autoimmune hepatitis (AIH) and alcoholic hepatitis (AH), are associated with substantial systemic toxicity. Long-term use may lead to osteoporosis, hyperglycemia, adrenal suppression, Cushingoid features, muscle wasting, and an increased risk of opportunistic infections. Moreover, treatment relapse rates in AIH remain high (20–30%) following taper or discontinuation, necessitating lifelong immunosuppression in many cases. In the setting of decompensated cirrhosis particularly with sepsis, gastrointestinal bleeding, or renal dysfunction steroids may be contraindicated, limiting their utility in severe ALD.

Immunosuppressive agents, including azathioprine, mycophenolate mofetil (MMF), and calcineurin inhibitors, pose additional risks such as bone marrow suppression, hepatotoxicity, nephrotoxicity, and lymphoproliferative disorders. Their narrow therapeutic index necessitates frequent laboratory monitoring, which may not be feasible for patients in rural or economically underserved regions, imposing both logistical and financial burdens.

In cholestatic liver diseases, ursodeoxycholic acid (UDCA) remains the standard therapy for primary biliary cholangitis (PBC); it improves biochemical markers and delays disease progression but does not significantly improve survival in advanced-stage PBC. For UDCA non-responders, obeticholic acid (OCA) has shown efficacy, yet its cost and contraindication in advanced cirrhosis limit broader application due to risk of hepatic decompensation.

Supportive treatments also present challenges. Lactulose, used for hepatic encephalopathy, frequently causes bloating, flatulence, and non-adherence. Rifaximin, though effective, is expensive for long-term prophylaxis. Non-selective beta-blockers (NSBBs) require careful titration to avoid hypotension and renal dysfunction, while diuretics can precipitate electrolyte imbalances, hyponatremia, and hepatorenal syndrome in cirrhotic patients. Moreover, conventional therapies do not effectively target fundamental drivers of liver injury, such as oxidative stress, lipotoxicity, mitochondrial dysfunction, and gut dysbiosis. These factors are central to the pathogenesis and progression of non-alcoholic steatohepatitis (NASH), drug-induced liver injury (DILI), autoimmune hepatitis, and alcohol-related liver disease, highlighting the need for multi-targeted therapeutic approaches that address the complex interplay of metabolic, immune, and environmental factors.

Beyond clinical limitations, socioeconomic and infrastructural barriers further hinder the effectiveness of standard treatments in regions like rural India, where access to specialist care, diagnostic tools, and advanced therapies is limited. High drug costs, long treatment durations, and adverse effect profiles contribute to non-compliance and poor outcomes, especially among economically disadvantaged populations. These gaps underscore the urgent need for novel hepatoprotective strategies. In this context, natural products and medicinal plants are emerging as promising alternatives. Many exhibit antioxidant, anti-inflammatory, anti-fibrotic, and immunomodulatory properties, with a lower incidence of side effects and greater patient acceptability. Preclinical and early clinical evidence suggests that these agents may offer multi-mechanistic benefits, addressing the root causes of liver injury and potentially improving both disease progression and quality of life for patients with chronic liver disorders.

Role Of Liver Transplantation:

Liver transplantation (LT) represents the definitive treatment for patients with end-stage liver disease (ESLD), acute liver failure, or early-stage hepatocellular carcinoma (HCC) that is not amenable to surgical resection. LT offers complete restoration of hepatic function, significantly improves survival, and enhances quality of life. Globally, 1-year survival rates post-transplant are approximately 85%, and 5-year survival rates exceed 70%, positioning LT among the most successful solid organ transplant procedures ^[38] .

• Indications For Liver Transplantation ^[38]:

Liver transplantation is indicated in a range of clinical scenarios, including:

1. Decompensated cirrhosis, presenting with ascites, hepatic encephalopathy, or variceal bleeding
2. Acute liver failure, as seen in acetaminophen toxicity or fulminant viral hepatitis
3. Unresectable early-stage HCC, particularly those meeting Milan or UCSF criteria
4. Inherited metabolic disorders such as Wilson’s disease, Crigler-Najjar syndrome, and progressive familial intrahepatic cholestasis (PFIC)
5. End-stage autoimmune or cholestatic liver diseases, including advanced AIH, PBC, and PSC

• Candidate Selection and Prioritization ^[39]:

The Model for End-Stage Liver Disease (MELD) score is the primary tool used to prioritize transplant recipients based on disease severity. It incorporates bilirubin, INR, creatinine, and sodium levels to predict short-term mortality, with higher scores indicating more urgent need. The Child–Pugh score also provides prognostic information, helping to stratify patients for transplant consideration.

Post-Transplant Management and Outcomes

Following transplantation, patients require lifelong immunosuppression to prevent graft rejection. Common regimens include:

• Tacrolimus (calcineurin inhibitor)
• Mycophenolate mofetil (antimetabolite)
• Prednisolone (glucocorticoid, tapered as tolerated)

While graft and patient survival rates are high, LT is associated with long-term risks, including:

• Acute and chronic rejection
• Infectious complications, due to immunosuppression
• Renal dysfunction
• Metabolic syndrome (diabetes, hypertension, dyslipidemia)
• Post-transplant malignancies

Regular follow-up and medication adherence are essential to manage these complications and ensure graft longevity.

Liver Transplantation in India: Current Landscape and Challenges:

In India, liver transplantation has seen substantial growth, particularly in tertiary care centers in cities like Delhi, Chennai, and Hyderabad. However, access to LT remains limited due to:

1. High costs, ranging from ?20–30 lakhs (USD $25,000–$37,000)
2. Lack of insurance coverage
3. Inadequate infrastructure in rural areas
4. Scarcity of deceased organ donors

As a result, living donor liver transplantation (LDLT) accounts for the majority of transplants, though this too depends on donor availability and recipient fitness. Efforts by organizations such as the National Organ and Tissue Transplant Organization (NOTTO) have improved awareness and regulatory coordination, but donor rates in India remain below global averages, limiting the reach of transplant programs.

• The Need for Preventive and Adjunctive Interventions ^[38,39]:

Given the economic and logistical constraints, liver transplantation remains inaccessible to a large segment of the Indian population. This underscores the critical need for preventive strategies and early-stage interventions that could delay or obviate the need for transplantation.

In this context, plant-based hepatoprotective therapies have garnered increasing attention. Medicinal plants such as:

• Phyllanthus niruri
• Picrorhiza kurroa
• Silybum marianum (milk thistle)
• Andrographis paniculata

Have demonstrated antioxidant, anti-inflammatory, anti-apoptotic, and anti-fibrotic properties in preclinical models of liver injury. These multifaceted mechanisms make them promising candidates for adjunctive therapy in chronic liver diseases, especially in settings with limited access to transplantation. The integration of such evidence-based phytotherapies into public health frameworks could significantly improve liver disease outcomes in resource-constrained settings while supporting cost-effective and culturally acceptable care models ^[39].

Many of these plants contain a variety of chemical components, including phenols, coumarins, lignans, essential oils, monoterpenes, carotenoids, glycosides, flavonoids, organic acids, lipids, alkaloids, and xanthines, which are associated with their liver-protective properties. The development of entirely plant-based hepatoprotective medications has gained importance globally. Medicinal plants are considered significant sources of hepatoprotective drugs, with about 170 phytoconstituents isolated from 110 plants belonging to 55 families reportedly having this activity. Over 87 plants are used in patented and proprietary multi-ingredient plant formulations in India. Scientific evaluation has often shown that active principles within plants are responsible for their therapeutic success. Herbal drugs are generally considered relatively non-toxic, safe, and often free from serious side effects.

CONCLUSION:

The etiology of liver disease is continually evolving with the global rise in obesity and T2DM, MASLD poses a growing health threat worldwide. From the above discussion it seems that liver health is very important for healthy life of humans. Moving forward, our current understanding of the pathogenesis has provided valuable insights and directed ongoing research efforts aimed at liver disease treatment. However, a comprehensive understanding of critical symptoms and their interactions during liver problem progression is essential to advance therapeutic strategies and improve patient health outcomes.

REFERENCES

1. Bruha.R, Dvorak.K, Petrtyl.J, “Alcoholic liver disease”, World J. Hepatol. 2012(4), Page No: 81–90.
2. Sakamoto.Y, Kokudo.N, Kawaguchi.Y, Akita.K, Clinical Anatomy of the Liver: Review of the 19th Meeting of the Japanese Research Society of Clinical Anatomy, 2017,Page No:72-76
3. Jain.R., Kumar.A, Sasturkar.S, Mukund.B, “Biliary Complications after Liver Transplant: Imaging Review and Minimally Invasive Management”, Dig. Dis. Interv, 2024,Page No:14-18
4. Malviya.K, Verma.D, “ A Importance of Anatomical Variation of the Hepatic Artery for Complicated Liver and Pancreatic Surgeries: A Review Emphasizing Origin and Branching. Diagnostics, 2023, Page No:123-131
5. Mondal.D, Das.K, Chowdhury, “A Epidemiology of liver diseases in India”, Clinical. Liver Disease, 2022,(19), Page No:114–117.
6. Sumadewi, K.T, “Embryology, anatomy and physiology of the liver: Review”. Indian J. Clin. Anat. Physiology, 2023, Page No:11-13
7. Wong.M.C, Huang.J, George.J, “The changing epidemiology of liver diseases in the Asia--Pacific region”,Nat Rev Gastroenterol Hepatol, 2019,(16), Page No:57–73.
8. Chen.W, Yang.A, Zhang.N, You. H, “Liver fibrosis, in: Sinusoidal Cells in Liver Diseases: Role in Their Pathophysiology, Diagnosis, and Treatment”, 2024, Page No:293–316.
9. Bataller.R, Arteel.G.E, Moreno.C, Shah.V, “Alcohol-related liver disease: Time for action”. J. Hepatol. 2019, Page No:59-63.
10. Ishak.K.G, Zimmerman.H.J, Ray.M.B, “Alcoholic Liver Disease: Pathologic, Pathogenetic and Clinical Aspects. Alcohol”, Clinical. Exp. Res. 1991, (15), Page No:45–66.
11. Liu.S.Y, Tsai.I.T, Hsu.Y.C, Alcohol-related liver disease: Basic mechanisms and clinical perspectives. Int. J. Mol. Sci, 2021.Page No:67-70.
12. Stewart.S.F, Day.C.P, “Alcoholic Liver Disease”, in: Zakim and Boyer’s Hepatology. 2012, Page No: 493–527.
13. Benedict.M, ZhangX, Non-alcoholic fatty liver disease: An expanded review. World J. Hepatol, 2017, Page No:22-23
14. Allen.A.M, Allen.A.M, Kim.W.R, Kim.W.R, Larson.J.J, Larson.J.J, Rosedahl.J, Rosedahl.J.K, Yawn.B.P, Yawn.B.P, McKeon.K, McKeon.K., Hay.J.E, Hay.J.E, 2016. The Epidemiology of Liver Diseases Unique to Pregnancy in a US Community: A Population-Based Study. Clin. Gastroenterol. Hepatol, 2016.Page No:33-37
15. Powell.E.E, Wong.V.W, Rinella.M. “Non-alcoholic fatty liver disease. Lancet 397”, 2021, Page No: 2212–2224.
16. Gougol.A, Clemente-Sanchez. A, Argemi.J, Bataller.R, Alcoholic Hepatitis. Clin. Liver Dis, 2021. Page No:111-117.
17. Berry.A.J,Viral hepatitis, Anesthesiol. Clin. North America, 1989, Page No:01-09.
18. Walsh.K, Alexander.G.J, Update on chronic viral hepatitis. Postgrad. Med. J. 2001,(77), Page No: 498–505.
19. Gitto.S, Vitale.G, Villa.E, Andreone.P, Update on alcohol and viral hepatitis. J. Clin. Transl. Hepatol, 2014,Page No:234-237.
20. Marcus.E.L, Tur-Kaspa.R, “Viral hepatitis in older adults”. J. Am. Geriatr. Soc, 1997, Page No:33-37.
21. Pisano. M.B, Giadans.C.G, Flichman.D.M, Ré, V.E, Preciado.M. V, Valva.P, Viral hepatitis update: Progress and perspectives. World J. Gastroenterol, 2021, Page No:222-223.
22. Torre.P, Aglitti.A, Masarone.M, Persico,M, “Viral hepatitis: Milestones, unresolved issues, and future goals”, World J. Gastroenterol, 2021, Page No:11-21.
23. Invernizzi.P, Mackay.I.R, Autoimmune liver diseases. World J. Gastroenterol, 2008,Page No:223-227.
24. Brewer. G.J, Wilson’s disease, in: Neurogenetics: Scientific and Clinical Advances, 2005,Page No:383–401.
25. Gitlin, J.D, Wilson Disease. Gastroenterology, 2003(125),Page No: 1868–1877.
26. Poujois.A, Woimant.F, Wilson ’ s disease?: A 2017 update. Clin. Res. Hepatol. Gastroenterol, 2018, Page No:145-152.
27. Gandon, Y, Oliví.D, Juhel.C, Rohou.T, Aub?.C, Diffuse liver diseases. EMC-Radiologie, 2004,Page No:33-37.
28. Singal.A.K, Mehta.H, Clemente-Sanchez.A, Arab.J.P, Dunn.W, Bataller.R, Alcohol-associated liver disease, in: Hepatology: An Evidence-Based Clinical Compendium: 2024, Volume 1-2. Page No: 761–803.
29. Szabo.G, Csak.T, Review Inflammasomes in liver diseases. J. Hepatol, 2012(57),Page No: 642–654.
30. Chilaka.V.N, Konje.J.C, European Journal of Obstetrics & Gynecology and Reproductive Biology Viral Hepatitis in pregnancy. Eur. J. Obstet. Gynecol. 2021(256), Page No: 287–296.
31. Kobelska-Dubiel.N, Klincewicz.B., Cichy.W, Liver disease in cystic fibrosis. Prz. Gastroenterol, 2014, Page No: 444-447.
32. Patel.D, McAllister.S.L, Teckman.J.H, Alpha-1 antitrypsin deficiency liver disease. Transl. Gastroenterol. Hepatol, 2021, Page No: 55-61.
33. Evans.H.M, Siew.S.M, Neonatal liver disease. J. Paediatr. Child Health, 2020, Page No: 277-279.
34. Frey.C.F, Zhu.Y, Liver Abscesses. Liver Surg, 1989(69), Page No: 259–271.
35. Martens.P, Nevens.F, “Budd-Chiari syndrome”, United Eur. Gastroenterol. J, 2015, Page No: 67-73.
36. Acharya.S.K, Viral diseases involving the liver, 1987, Page No: 22-27.
37. Odenwald.M.A, Paul.S, Viral hepatitis: Past, present, and future. World J. Gastroenterol, 2022, Page No: 44-48.
38. Carbone.M, Neuberger.J.M, Autoimmune liver disease, autoimmunity and liver transplantation. J. Hepatol, 2014, Page No: 144-149.
39. Ali.M, And M.K.I.J, A recent update on hepatoprotective potential of herbal plant. Suresh Gyan Vihar Univ. Int. J. of Environment, Sci. and Technology, 2015(1), Page No: 25–50.